Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026)
Precision Biosciences (DTIL) reported Cash from Investing Activities of -$114000.0 for Q1 2026, up 63.69% year-over-year from -$69642.0 in Q1 2025, and up 64.92% quarter-over-quarter from -$325000.0 in Q4 2025.
Precision Biosciences (DTIL) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Cash from Investing Activities data on file, last reported at -$114000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$114000.0, up 63.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$434000.0 (up 13.72% YoY), and the FY2025 annual result was -$634000.0, down 194.88% from the prior year.
- Cash from Investing Activities climbed to -$114000.0 in Q1 2026 per DTIL's latest filing, from -$325000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $7.6 million in Q3 2023 and troughed at -$1.1 million in Q3 2022.
- A 5-year average of $91000.0 and a median of -$114000.0 in 2026 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 793.94% in 2023, then plunged 1107.69% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$632000.0 in 2022, then jumped by 106.65% to $42000.0 in 2023, then slumped by 330.95% to -$97000.0 in 2024, then slumped by 235.05% to -$325000.0 in 2025, then soared by 64.92% to -$114000.0 in 2026.
- Business Quant data shows DTIL's Cash from Investing Activities at -$114000.0 in Q1 2026, -$325000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -114,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -114,000.00 |
| Mar 31, 2026 | -114,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Mar 31, 2025 | -314,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Dec 31, 2023 | 42,000.00 |